262 related articles for article (PubMed ID: 33319440)
1. Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
Jacob L; Rickwood S; Rathmann W; Kostev K
Diabetes Obes Metab; 2021 Apr; 23(4):910-915. PubMed ID: 33319440
[TBL] [Abstract][Full Text] [Related]
2. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
5. Changes in the use of glucose-lowering drugs: A Danish nationwide study.
Pottegård A; Andersen JH; Søndergaard J; Thomsen RW; Vilsbøll T
Diabetes Obes Metab; 2023 Apr; 25(4):1002-1010. PubMed ID: 36514856
[TBL] [Abstract][Full Text] [Related]
6. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Verburg AFE; van den Donk M; Wiersma T
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
[TBL] [Abstract][Full Text] [Related]
7. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.
Bielka W; Przezak A; Pawlik A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299225
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.
Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
Prim Care Diabetes; 2019 Jun; 13(3):221-232. PubMed ID: 30573348
[TBL] [Abstract][Full Text] [Related]
9. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
10. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
11. Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany.
Bongaerts B; Kollhorst B; Kuss O; Pigeot I; Rathmann W
Exp Clin Endocrinol Diabetes; 2022 Sep; 130(9):587-595. PubMed ID: 34942670
[TBL] [Abstract][Full Text] [Related]
12. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
13. Glucose lowering and the kidney: are all drug classes equal?
Wong MG; Jardine M; Perkovic V
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
[No Abstract] [Full Text] [Related]
14. How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Sukkar L; Young T; Jardine MJ
Kidney Blood Press Res; 2020; 45(6):823-836. PubMed ID: 33271545
[TBL] [Abstract][Full Text] [Related]
15. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
16. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
Tahrani AA; Barnett AH; Bailey CJ
Nat Rev Endocrinol; 2016 Oct; 12(10):566-92. PubMed ID: 27339889
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients.
Hasan SS; Kow CS; Bain A; Kavanagh S; Merchant HA; Hadi MA
Expert Opin Pharmacother; 2021 Feb; 22(2):229-240. PubMed ID: 33054481
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
20. New Agents for the Treatment of Type 2 Diabetes.
Libianto R; Ekinci EI
Crit Care Clin; 2019 Apr; 35(2):315-328. PubMed ID: 30784612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
